 Shares of Avadel Pharmaceuticals NASDAQ:AVDL decreased 1.3 in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share increased 47.83 year over year to 0.12, which missed the estimate of 0.10.Revenue of 10,091,000 declined by 42.51 year over year, which beat the estimate of 7,370,000.Looking Ahead Avadel Pharmaceuticals hasnt issued any earnings guidance for the time being.Revenue guidance hasnt been issued by the company for now.How To Listen To The Conference Call Date: Aug 10, 2020View more earnings on AVDLTime: 08:30 AMET Webcast URL: Stock Performance Companys 52-week high was at 13.4952-week low: 1.82Price action over last quarter: down 9.64Company Description Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company markets products in both the primary care and sterile injectables markets. Its products portfolio includes Bloxiverz, Vazculep phenylephrine hydrochloride injection, Akovaz ephedrine sulfate injection, Karbinal ER carbinoxamine maleate extended-release oral suspension, AcipHex Sprinkle rabeprazole sodium, Cefaclor for Oral Suspension, 125 mg5 mL, 250 mg5 mL and 375 mg5 mL, and Flexichamber. Majority of the revenue is derived from the United States.See more from Benzinga Royal Caribbean Cruises: Q2 Earnings Insights Motorcar Parts of America: Q1 Earnings Insights LiqTech International: Q2 Earnings InsightsC 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 